Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs

At present there are no drugs for the treatment of chronic liver fibrosis that have been approved by the Food and Drug administration of the United States. Telmisartan, a small-molecule antihypertensive drug, displays antifibrotic activity, but its clinical use is limited because it causes systemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Golder, Matthew R., Liu, Jenny, Andersen, Jannik N., Shipitsin, Michail V., Vohidov, Farrukh, Nguyen, Hung V.-T., Ehrlich, Deborah C., Huh, Sung Jin, Vangamudi, Bhavatarini, Economides, Kyriakos D., Neenan, Allison M., Ackley, James C., Baddour, Joelle, Paramasivan, Sattanathan, Brady, Samantha W., Held, Eric J., Reiter, Lawrence A., Saucier-Sawyer, Jennifer K., Kopesky, Paul W., Chickering, Donald E., Blume-Jensen, Peter, Johnson, Jeremiah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433387/
https://www.ncbi.nlm.nih.gov/pubmed/30918745
http://dx.doi.org/10.1038/s41551-018-0279-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433387/
https://www.ncbi.nlm.nih.gov/pubmed/30918745
http://dx.doi.org/10.1038/s41551-018-0279-x

Ejemplares similares